Key publications of the Cardiovascular Pharmacology group

Macrophages and atherosclerotic lesions The infiltration of monocytes in the arterial wall, their differentiation to macrophages, and the subsequent accumulation of cholesterol in these macrophages initiate the process of atherosclerosis. We study the importance of specific genes in macrophages for…

The Division of BioTherapeutics at the Leiden Academic Centre for Drug Research (LACDR) is aimed at a smoother and speedier transition from preclinical research to pharmacological interventions, and the delivery of drugs in the human body by use of small molecules and biologics.

Ilze Bot wants to reduce the prevalence of cardiovascular diseases. Her research focuses on mast cells, which protect us from infections but can also make us ill.

The Immune Activation and Tolerance group is headed by Dr. Bram Slütter. Vaccination is an experimental, but promising, treatment strategy for atherosclerosis. Previous work has shown that immunization of mice with modified LDL particles can reduce atherosclerotic lesion development, however such vaccines…

Both psoriasis and atheroslcerosis are diseases characterized by a chronic and systemic inflammatory profile with local lipid disturbances that alter the barrier function of the skin (psoriasis) and cause the development of atherosclerotic plaques (atherosclerosis).

In her inaugural lecture on 11 September, Miranda van Eck, Professor of Cardiovascular and Metabolic Therapeutics, addressed her research related to developing medications to keep our blood vessels clean.

The Cardiovascular Pharmacology research group headed by Ilze Bot aims to elucidate the mechanisms that underlie atherosclerotic plaque destabilization, which is the key process that leads to acute cardiovascular syndromes such as a myocardial infarction or stroke.

Key publications of the Aging and Immunity group

PhD defence

For more information regarding ongoing research projects, please contact Prof. Miranda van Eck.

Research in the BioTherapeutics research programme is aimed at a smoother and speedier transition from preclinical research to pharmacological interventions, and the delivery of drugs in the human body by use of small molecules and biologics.

Leiden researchers and students receive national and international awards in recognition of their valuable performance in the areas of science and society.

PhD defence

Would you like to know more about our research using laboratory animals or our studies on alternatives to animal testing? If so, take a look at the news articles on the right-hand side of the page (for mobile users, see the bottom of the page).

The objective of the PhD Education and Supervision program is to educate PhD candidates in becoming professionals who are competent to conduct scientific research in the field of the pharmaceutical sciences independently.

The division of BioTherapeutics consists of the former divisions Biopharmaceutics and Drug Delivery Technology.

In the Drug Research theme, we primarily work with rodents. Rodents, such as mice, are one of the most common laboratory animals. These small mammals are easily housed and exhibit a rapid rate of reproduction.

This minor is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs. Students learn how disease and drug-induced alterations in signaling pathways can be used for the discovery of new drug targets and the development of personalized drugs.

Source: Eur J Med Chem (2015)

Through metabolism, biochemical processes give rise to the complexity of life. Acquired and inborn errors in metabolism underlie many diseases occurring in man. The challenge for present day medical biochemistry is to find, and integrate, pieces of information at molecular, cell and organismal level…

The Leiden Academic Centre for Drug Research (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development.

At Leiden University, in both our biomedical and biological research, we use laboratory animals. Learn more about these specific areas of research and the goals we aim to achieve through these studies.

From molecule, to cell, to organism. The high-level drug research at the Cell Observatory aimes at reducing the spread of cancer and developing new medicines for tuberculosis.

Supervisor: Natalia Ortiz Zacarías

Source: Bioorg Med Chem, Volume 23, Issue 14, pp. 4034-49 (2015)

PhD defence

PhD defence

Is it possible to diagnose diseases using molecular switches? The new international consortium LogicLab will address this question. Leiden chemist Sylvestre Bonnet and Leiden pharmacologist Thomas Hankemeier are involved in the project. LogicLab will run for four years and will receive over 3.5 million…

Dr. Amanda Foks obtained a fellowship from the dr. E. Dekker-program for the project ' Can promotion of efferocytosis induce regression of atherosclerosis?', in which she aims to identify novel targets to promote regression of atherosclerosis. This research grant allows her to initiate independent research…

Publication by: Amanda Foks, Gijs van Puijvelde, Jolien Wolbert, Mara Kröner, Vanessa Frodermann, Thomas van der Heijden, Peter van Santbrink, Louis Boon, Ilze Bot and Johan Kuiper. Cardiovascular Research. 2016;111(3):252-261.

Current research at the Skin Barrier and Vaccination group.

Dr Ilze Bot (LACDR) has been appointed professor of Cardiovascular Pharmacology with effect from 1 March. A recognition of her work as a scientist. 'This allows me to continue and expand my line of research within the LACDR and Leiden University.'

Amanda Foks (Division of BioTherapeutics) has been awarded a Horizon 2020, ERA-CVD joint transnational cardiovascular research grant. She will lead a consortium consisting of early career European scientists (Dimitrios Tsiantoulas, Medical University of Vienna, Austria; Julia Polansky-Biskup, Charité…

An overview of the research at the Biologics Formulation group

A tantalizing concept that has emerged in our recent research is binding kinetics. An important parameter is residence time (RT), a direct reflection of how long a drug stays bound to its target. This parameter is of crucial importance, because drug action lasts only as long as the receptor-ligand complex…

In the Netherlands, 1.55 million people suffer from cardiovascular diseases. Yet, acute cardiovascular events, such as a heart attack or stroke, often occur unexpectedly. That is because many people do not know they are at risk for such an event. Immunological researcher Amanda Foks and her colleagues…

The Heart Foundation has portrayed researchers Johan Kuiper and Ilze Bot of the Leiden Academic Centre for Drug Research (LACDR) who fight heart and brain infarcts in the lab.

Liposomes – nano-sized spheres composed of fatty molecules – are very promising for vaccination. Bio-pharmaceutical scientist Naomi Benne discovered that the immune response in animal models can be steered by varying the charge of the liposomes. She obtained her PhD degree on 8 September for this research,…

New research published in the Journal of Leukocyte Biology suggests that these changes to the behavior of the immune system are persistent and can continue even after diet is improvedAlmost everyone knows that improving your eating habits will most likely improve your health. What most people may not…

On this page you will find an overview of awards and prizes granted to our staff and students in 2024, as well as special appointments at Leiden University and other institutions.

There are many complex links in the chain that provides patients with new drugs: from fundamental science, to clinical tests, to production. The entire chain can be found in Leiden. Leiden University, the Leiden University Medical Center (LUMC) and the businesses at the Leiden Bio Science Park (LBSP)…

On November 1st, 2024, professor Johan Kuiper will retire and be appointed as emeritus professor at Leiden University. Since November 2008, Johan Kuiper was professor of Therapeutic Immunomodulation in the division of, at that time, Biopharmaceutics (which later on became the division of BioTherapeutics)…

Marie Depuydt has won the Van Wersch Springboard Prize. She was awarded the prize on 28 November during the annual Fall symposium. There were seven nominees in total, but the selection committee unanimously chose Depuydt as the winner.

As a bachelor student of Bio-Pharmaceutical Sciences, Femke Vlaswinkel wrote a research proposal she was allowed to carry out in her master’s BPS. Femke subsequently graduated with honors. Her research was published in the journal Scientific Reports, she won an award from the Dutch Pharmacy Society…

Publication by: Anouk Wezel, Sabine Welten, Wida Razawy, Max Lagraauw, Margreet de Vries, Eveline Goossens, Martin Boonstra, Jaap Hamming, Ekambar Kandimalla, Johan Kuiper, Paul Quax, Yaël Nossent and Ilze Bot. Annals of Surgery. 2015;262:841-848.

Improving healthcare with our scientific discoveries: that is the goal of pharmaceutical research at Leiden University. And there’s a lot involved in that. Our research starts with the discovery of the effect achieved by a particular substance, and sometimes continues all the way through to the development…